LONDON, UK / ACCESSWIRE / January 16, 2018 / Active-Investors.com has just released a free research report on Boston Scientific Corp. (NYSE: BSX). If you want access to this report all you need to do ...

System offers multiple non-drug therapies for people with chronic pain PARIS, Jan. 31, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Spectra ...

Boston Scientific Corporation's BSX successful result from its WHISPER randomized controlled trial (RCT) further boosts its neuromodulation business. This announcement follows the recent FDA approval ...

The FDA approved Boston Scientific's Spectra WaveWriter Spinal Cord Stimulator System. Here's what you should know: 1. The system is the first and only FDA-approved system that simultaneously provides ...

Boston ScientificBSX is hitting headlines with successive new developments, the latest feat being the company's Spectra WaveWriter Spinal Cord Stimulator System (SCS) getting an FDA nod. Per Boston ...

Boston’s recall comes at a time where several players in the medtech industry are facing personal injury lawsuits over SCS system malfunctions.

Boston Scientific Corp. won a nod from the FDA to market its Spectra Wavewriter spinal cord stimulator (SCS) system to treat pain. The Marlborough, Mass.-based company said its SCS works by sending ...

DUBLIN--(BUSINESS WIRE)--The "Spinal Cord Stimulators Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. A spinal cord stimulator is a small device that aids in managing the ...

Boston Scientific, Inc. BSX recently received FDA approval for an expanded indication of the WaveWriter Alpha Spinal Cord Stimulator (“SCS”) Systems. With this approval, the system will be available ...